BhutanTuberculosis profile
Population  2016 <1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.16 (0.1–0.22) 20 (13–28)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.2 (0.15–0.27)
Incidence  (includes HIV+TB) 1.4 (1.1–1.8) 178 (137–226)
Incidence (HIV+TB only) <0.01 (<0.01–0.011) 0.94 (0.61–1.3)
Incidence (MDR/RR-TB)** 0.19 (0.13–0.24) 23 (16–31)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.08 (0.06–0.1) 0.71 (0.53–0.88) 0.79 (0.59–0.98)
Males 0.09 (0.067–0.11) 0.55 (0.41–0.69) 0.64 (0.48–0.8)
Total 0.17 (0.13–0.21) 1.3 (0.94–1.6) 1.4 (1.1–1.8)
TB case notifications, 2016  
Total cases notified 1 145
Total new and relapse 1 139
          - % tested with rapid diagnostics at time of diagnosis 26%
          - % with known HIV status 100%
          - % pulmonary 51%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.11 (0.07–0.17)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 6 <1%
          - on antiretroviral therapy 3 50%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  70
(52–87)
Estimated % of TB cases with MDR/RR-TB 11% (8.5–15) 18% (7.7–34)  
% notified tested for rifampicin resistance 100% 100% 1 145
MDR/RR-TB cases tested for resistance to second-line drugs   55
Laboratory-confirmed cases MDR/RR-TB: 55, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 55, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 92% 963
Previously treated cases, excluding relapse, registered in 2015 75% 12
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014 90% 61
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
6.3% (5.8–7)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data